Mehmet Metin Şeker

The negative prognostic impact of bone metastasis with a tumor mass

OBJECTIVE: Typically, bone metastasis causes osteolytic and osteoblastic lesions resulting from the interactions of tumor cells with osteoclasts and osteoblasts. In addition to these interactions, tumor tissues may grow inside bones and cause mass lesions. In the present study, we aimed to demonstrate the negative impact of a tumor mass in a large cohort of patients with bone metastatic cancer. METHODS: Data from 335 patients with bone metastases were retrospectively reviewed. For the analysis, all patients were divided into three subgroups with respect to the type of bone metastasis: osteolytic, osteoblastic, or mixed. The patients were subsequently categorized as having bone metastasis with or without a tumor mass, and statistically significant differences in median survival and 2-year overall survival were observed between these patients (the median survival and 2-year overall survival were respectively 3 months and 16% in patients with a tumor mass and 11 months and 26% in patients without a tumor mass; p<0.001). RESULTS: According to multivariate analysis, the presence of bone metastasis with a tumor mass was found to be an independent prognostic factor (p=0.011, hazard ratio: 1.62, 95% confidence interval: 1.11–1.76). Bone metastasis with a tumor mass was more strongly associated with osteolytic lesions, other primary diseases (except for primary breast and prostate cancers), and spinal cord compression. CONCLUSION: Bone metastasis with a tumor mass is a strong and independent negative prognostic factor for survival in cancer patients.

Is there diagnostic and prognostic importance of serum anti-p53 antibody level in lung cancer?

Department of Nuclear Medicine, Cumhuriyet University School of Medicine, Sivas-Turkey Department of Radiation Oncology, Cumhuriyet University School of Medicine, Sivas-Turkey Department of Chest Diseases, Cumhuriyet University School of Medicine, Sivas-Turkey Department of Biochemistry, Omer Halisdemir University School of Medicine, Niğde-Turkey Department of Biochemistry, Cumhuriyet University School of Medicine, Sivas-Turkey Department of Medical Oncology, Turgut Ozal University Faculty of Medicine, Ankara, Turkey Corresponding author: Zekiye Hasbek, Department of Nuclear Medicine, Cumhuriyet University, Sivas E-mail: hasbekz@yahoo.com Received/Accepted: March 28, 2017 / July 24, 2017 Conflict of interest: There is not a conflict of interest.

The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer.

Objective: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. Methods: Serum anti-p53 Ab level was studied in three groups. Patients who underwent 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent 18F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers. Results: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUVmax, SUVave, TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05). Conclusion: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion.

Baş boyun kanserlerinde prognoz: Hasta ve tedaviyle ilişkili faktörlerin önemi

Department of Radiation Oncology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey Department of Radiation Oncology, Dr. Abdurrahman Yurtarslan Ankara Oncology Training and Research Hospital, Ankara, Turkey Department of Medical Oncology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey Department of Nuclear Medicine, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey Clinical Research / Klinik Araflt›rma